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Available online 17 February 2016The V600EBRAF oncogenicmutation is detected in awide range of human cancers and induces hyperactivation of the
downstream MEK–ERK signalling cascade. Although output of the BRAF–MEK–ERK pathway is regulated by feed-
forward RAF activity, feedback control also plays an important role. One such feedback pathway has been identiﬁed
in Caenorhabditis elegans and involves ERK-mediated phosphorylation of BRAF within a CDC4 phosphodegron
(CPD), targeting BRAF for degradation via CDC4 (also known as FBXW7), a component of the SKP1/CUL1/F-box
(SCF) E3 ubiquitin ligase complex. Here we investigate this pathway in mammalian cells. Short-term expression
of autochthonous V600EBRAF in mouse embryonic ﬁbroblasts (MEFs) leads to down-regulation of BRAF protein
levels in a proteasome-dependent manner and V600EBRAF has a reduced half-life compared to WTBRAF in
HEK293T cells. These effects were reversed by treatment with the MEK inhibitor PD184352. We have identiﬁed
the equivalent CPD at residues 400–405 in human BRAF and have found that mutation of ERK phosphorylation
sites at residues T401 and S405 in V600EBRAF increases the half-life of the protein. While BRAF and FBXW7 co-
immunoprecipitated, the overexpression of FBXW7 did not inﬂuence the half-life of either WTBRAF or V600EBRAF.
Furthermore, disruption of the substrate-binding site of mouse FBXW7 using the R482Q mutation did not affect
the interaction with BRAF and the expression levels of WTBRAF and V600EBRAF were not altered in MEFs derived
frommice with the homozygous knockin R482QFBXW7mutation. Overall these data conﬁrm the existence of a neg-
ative feedback pathway by which BRAF protein stability is regulated by ERK. However, unlike the situation in
C. elegans, FBXW7 does not play a unique role in mediating subsequent BRAF degradation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The BRAF protein kinase is a key component of the RAF–MEK–ERK
signalling cascade. This pathway plays a major role in controlling nu-
merous cellular events including cell proliferation, survival, differentia-
tion and migration [1,2]. Tight regulation of the pathway is vital for
normal cell, tissue and whole body homeostasis. This is evidenced by
the fact that hyperactive, oncogenic forms of BRAF are prevalent in sev-
eral human cancers [3]. The V600EBRAF mutation is the most common, mitogen-activated protein ki-
; CPD, CDC4 phosphodegron;
ethylsulphoxide; MEFs, mouse
lysis buffer; GFP, green ﬂuores-
udies, University of Leicester,
Insurgentes Sur 3700-C, Col.
. This is an open access article underBRAF mutation detected in human cancers and is thought to mediate
its transforming effects by deregulation of the MEK–ERK pathway [4–
6]. Loss of function mutations in components of the pathway such as
BRAF also give rise to embryonic lethality with a failure to thrive associ-
ated with placental failure [7,8].
The mechanisms of regulation of the ERK pathway have been sub-
jected to extensive investigation with evidence showing that the path-
way can be controlled by feed-forward and feedback loops [9–11].
Regulatory loops fall into immediate and late temporal domains. The
immediate responses include protein–protein interactions such as di-
merization [12–14] and covalent protein modiﬁcations particularly cy-
cles of phosphorylation and dephosphorylation [15–17], both of which
inﬂuence RAF activation/deactivation and subsequent downstream sig-
nalling. Late events involve newly synthesised proteins, for example the
induction of expression of adapters SPROUTYs and SPREDS [18–20]
as well as phosphatases [21–23] that have been shown to suppress
ERK pathway activity through feedback mechanisms. The activity of
feedback control pathways is important in cancer development as
evidenced by the fact that disabled feedback inhibitory pathways are
detected in V600EBRAF transformed cells [24], while clinical andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the ERK pathway being tumour suppressors [25].
Regulation of protein stability is an important factor in controlling
signalling pathway output. An example of this is for the EGF receptor
whereby ligand-induced autophosphorylation allows recruitment of
the CBL E3 ubiquitin ligase, which controls EGFR internalisation and
degradation [26,27]. With regard to RAF, the correct folding and
stabilisation of the proteins is dependent on the molecular chaperone
HSP90 complex [28] and pharmacological inhibition of HSP90 leads to
their ubiquitin-mediated degradation, particularly for V600EBRAF
which shows a greater dependence on HSP90 than WTBRAF, CRAF or
ARAF [29,30]. A study using siRNA has shown a requirement for the
E3 ubiquitin ligase Cullin-5 in mediating V600EBRAF degradation follow-
ing HSP90 inhibition [31]. The Ring ﬁnger protein 149 (RNF149) has
also been proposed to be an E3 ubiquitin ligase active operating on
the kinase domain of WTBRAF [32] while a further study in
Caenorhabditis elegans identiﬁed that the BRAF homologue, LIN-45, is a
substrate for the multiprotein E3 ubiquitin ligase Skp1/Cul1/F-box
(SCF) complex [33]. The F-box containing substrate receptor SEL-10
(FBXW7 inmammals) was shown to target LIN-45 through a conserved
Cdc4 phosphodegron (CPD) and, additionally, the ERK homologue
MPK-1 was found to be required for controlling LIN-45 degradation
through the CPD in a negative feedback loop [33].
Here, we have investigated BRAF protein turnover in mammalian
cells. UsingMEFs derived frommice bearing a conditional knockin allele
for V600EBRAF [34]we show that expression of V600EBRAF leads to down-
regulation of BRAF protein expression. This downregulation is not asso-
ciated with alterations in Braf mRNA levels, but can be rescued by
proteasome and MEK inhibition. Ectopically expressed V600EBRAF
also has a shorter half-life by ~3 h than WTBRAF and this can be rescued
by MEK inhibition. A conserved CPD at residues 400–405 in human
BRAF was identiﬁed and we show that the feedback regulation can in
part be explained by ERK-mediated phosphorylation of T401 and S405
since mutation of these residues increases the half-life of V600EBRAF.
However, although BRAF has the capability to bind to FBXW7, FBXW7
over-expression or loss of function does not alter either WTBRAF or
V600EBRAF protein stability, suggesting that this E3 ubiquitin ligase com-
ponent is not uniquely involved in regulating mammalian BRAF turn-
over. We also demonstrate an association between this novel feedback
pathway and the oncogene-induced senescence phenotype.
2. Materials and methods
2.1. Animal work
Braf+/LSL-V600E mice have been described previously [34] and the
induction of lung tumour development by intercrossing with the
CreER™ strain [35] has been reported in [36]. The conditional knockin
Fbxw7+/LSL-R482Q mice have been previously reported [37]. All animal
experiments were performed according to local ethical and UK Home
Ofﬁce guidelines, under regulatory approval. Haematoxylin and Eosin
(H&E) staining of parafﬁn-embedded sections was performed as de-
scribed [34]. PCR genotyping of BRAFV600E ﬂoxed and Cre-recombined
alleles was performed using methods and primers described in [34]
and detection of the Cre-recombined allele for the Fbxw7R482Q alleles
using PCR is described in Davis et al. 2011 [37]. MEFs were derived by
timed matings between relevant mouse strains and embryos were har-
vested at embryonic day 14.5 as described [38].
2.2. Cell culture and treatments
MEFs were cultured in DMEM with 10% (v/v) Foetal Calf Serum
(FCS) and 1% (v/v) penicillin and streptomycin (P-S) at 10% CO2. They
were plated at a density of 2x105 cells/well of a 6-well dish and infected
with 4 × 107 PFUof Adenoviral Cre (AdCre) for 2 h in 2ml ofmedia lack-
ing FCS and P-S. Media was replaced and cells were cultured for up to96 h. For MEK inhibition, 1 μM PD184352 in DMSO was added 48 or
72 h after AdCre infection. In both cases, cells were harvested 24 h
after PD184352 addition. For proteasome inhibition, 30 μMMG132 in
DMSO or 0.5 μMEpoxomicin in DMSOwere added for the last 5 h before
harvesting. HEK293T cells were cultured in MEF media and transfected
with 5 μg plasmid using Lipofectamine 2000 in accordance with the
manufacturer's instructions (Invitrogen). Cells were incubated for 48 h
before harvesting. NIH3T3 cells were cultured as for MEFs and
transfected with expression vectors using Lipofectamine 2000. Human
cancer cell lines were grown in MEF media and treated with or without
1 μM PD184352 in DMSO for 6–48 h before harvesting.
2.3. Western blot analysis
Cells and lung tissue were lysed with gold lysis buffer (GLB) as de-
scribed previously [39]. The soluble fraction (SF)was obtained by taking
the supernatant following centrifugation at 13,000 rpm for 10 min at
4 °C. The insoluble fraction (IF) was obtained by treating the pellets
with 1× Sample Buffer (0.05mMTris pH 6.8, 2% (v/v) SDS, 0.1% Glycer-
ol), vortexing for 1min and subsequently boiling for 5min at 95 °C. Pro-
tein concentrations were measured by the Bradford assay (SF) or BCA
protein assay kit (IF), both obtained from Pierce and following the
manufacturer's guidelines. The following antibodies were used for anal-
ysis: BRAF (Santa Cruz 5284), ERK2 (Santa Cruz SC154), Phospho-ERK1/
2 (Cell Signalling 9101), Phospho-MEK1/2 (Cell Signalling 9154S),
GAPDH (EMD Millipore MAB374), β-ACTIN (Sigma S-A2103), MYC-
TAG (Santa Cruz SC40), GFP (ABcam AB6556) and FLAG (Sigma F3165).
2.4. Plasmids and site-directed mutagenesis
Plasmids used for half-life experiments were either the pEF Myc-
taggedBRAFWT or pEFMyc-tagged BRAFV600E expression vectors as previ-
ously described [3]. Site directed mutagenesis was performed using the
Gene Tailor site-directed mutagenesis system (Invitrogen). For co-
immunoprecipitations, vectors expressing GFP-BRAFWT, GFP-BRAFV600E
or empty GFP vector were used together with vectors expressing
WTFBXW7 or R482QFBXW7.
2.5. Immunoprecipitations
HEK293T cells were transfected with the appropriate plasmid vectors
and GLB soluble protein lysates were generated. For GFP vectors, 200 μg
protein lysate was incubated with 20 μl GFP-TRAP beads (Chromotek)
in a volume of 500 μl with GLB lysis buffer rotating at 4 °C overnight.
For Myc-tagged vectors, 200 μg protein lysate was incubated with 15 μl
of the 9E10 antibody (200 μg/ml; Santa Cruz SC40) together with 25 μl
of Dynabeads protein G (Life Technologies) in a volume of 500 μl with
GLB lysis buffer rotating at 4 °C overnight. Immunoprecipitated proteins
were washed three times in GLB lysis buffer before resuspension in
Laemmli buffer and boiling at 95 °C for 5 min.
2.6. Pulse–chase experiments
HEK293T cells were transiently transfected with relevant vectors as
above in triplicate. 48 h after transfection cells were washed twice
with sterile PBS and cultured in 3 ml of Met/Cys-free Dulbecco's modi-
ﬁed Eagle's medium (Invitrogen) supplemented with 2 mM L-
glutamine (Sigma) and 5% (v/v) dialysed FCS (Invitrogen) for 1 h at
37 °C. The cells were labelledwith 50 μl of EXPRE35S35S protein labelling
mixture (100 μCi/dish; PerkinElmer Life Sciences) for 3 h at 37 °C. After
extensive washing, chase was initiated by adding 3 ml of MEF media to
each dish and cells were lysed at appropriate time points in 500 μl of
cold radioimmune precipitation assay buffer (20 mM Tris pH 7.5,
150 mM NaCl, 2 mM EDTA, 10% (v/v) glycerol, 1% (v/v) NP40, 1 mM
phenylmethylsulfonyl ﬂuoride, 1 mM NaV3O4, and 1 mM NaF). The
samples were left on ice for 30 min to allow complete lysis, and then
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ed and protein levels quantitated using the Bradford assay (Pierce).
Samples were subjected to immunoprecipitation as described above,
followed by SDS-PAGE. Gels were ﬁxed in 50% (v/v) methanol and
10% (v/v) acetic acid for 30 min, washed with water several times,
dried under vacuumand then exposed to a phosphoimager screen over-
night. For theMEK inhibitor experiments, 1 μMPD184352 or DMSO car-
rier control was added at the beginning of the chase and retained in the
culture media throughout the time-course.
2.7. Gel and blot quantitations
For Western blots, Image J software was used to quantitate protein
levels. The background on the blots was ﬁrst subtracted from the pixel
counts for each band and ﬁnal valueswere divided by the values obtain-
ed for loading controls. The control sampleswere set at 1.0 and all other
samples were calibrated accordingly into Arbitrary Units (AU). For half-
life determination, the intensity of each individual band was quantitat-
ed using the phosphoimager Quant programme (GE HealthCare). TheFig. 1. Downregulation of BRAF protein levels following V600EBRAF expression in MEFs. (A) Det
infected with AdCre for up to 96 h, DNA was isolated and PCR assays undertaken to identify LS
without AdCre for 96 h. (B) Drop in BRAF protein levels following BRAFV600E expression. Solub
indicated following AdCre treatment. Protein lysates were analysed by immunoblot for BRAF
independent experiments are shown. (C) BRAF protein quantitation. BRAF protein levels were
at 1.0 and all other samples were calibrated accordingly into Arbitrary Units (AU). Data repre
and three experiments of three independent MEFs for Braf+/+ MEFs. (D) BRAF expression leve
Braf+/LSL-V600E that had been treated with AdCre for 96 h and plated at high (H) or low (L) de
loading control. (E) Analysis of phosphoMEK and phosphoERK. Soluble protein lysates w
treatment. Protein lysates were analysed by immunoblot for BRAF, phosphoMEK, phosphoERKhalf-life was determined to be the point at which 50% of the protein
remained relative to that at t = 0.
2.8. Quantitative RT-PCR
Total RNA was extracted from MEFs using the RNeasy Mini Kit
(Qiagen) and 0.5 μg RNA was reverse-transcribed using Superscript III
(Invitrogen) according to the manufacturer's instructions. Quantitative
RT-PCR was performed as described [40] using SYBRGreen (BioRad) in
a LightCycler® 480 Real-Time PCR (Roche). Primers used were: Gapdh
For: 5′-AGG TCG GTG TGA ACG GAT TTG-3′ and Rev: 5′-TGT AGA CCA
TGT AGT TGA GGT CA-3′; Braf For: 5′-GAA TGT GAC AGC ACC CAC AC-
3′ and Rev: 5′-ATA AGC TGG AGC CCT CAC - 3′.
2.9. Statistical analysis
Comparison between any two groupswas performed by the student's
t test. P values of b0.05 were considered statistically signiﬁcant.ection of LSL and Lox alleles by PCR. Primary MEFs with the Braf+/LSL-V600E genotype were
L and Lox alleles. The photographs show the morphology of Braf+/LSL-V600E MEFs with and
le protein lysates were generated from Braf+/+ and Braf+/LSL-V600E MEFs at the time points
and phosphoERK with GAPDH as a loading control. Representative immunoblots for four
quantitated using Image J analysis of Western blot signals. The control samples were set
sent mean ± SD of four experiments of four independent MEFs for Braf+/LSL-V600E MEFs
l is not affected by cell density. Soluble protein lysates were generated from Braf+/+ and
nsity. Protein lysates were analysed by immunoblot for BRAF and GAPDH was used as a
ere generated from Braf+/LSL-V600E MEFs at the time points indicated following AdCre
with GAPDH as a loading control.
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3.1. Expression of V600EBRAF down-regulates BRAF protein levels
We have previously generated conditional knockin Braf+/LSL-V600E
mice that allow expression of the oncogenic V600EBRAF protein from
one allele of the endogenous Braf gene following Cre-mediated recom-
bination [34]. MEFs were derived from these mice and AdCre delivered
to the cells ex vivo. FollowingAdCre treatment, recombination of the LSL
allele was induced, generating the Lox-V600E allele with virtual 100%
recombination at 96 h post-Cre treatment (Fig. 1A). The cells weremor-
phologically transformed following V600EBRAF expression (Fig. 1A).
The levels of expression of the BRAF protein were monitored by
immunoblot analysis (Fig. 1B) and quantitation (Fig. 1C) in both
Braf+/LSL-V600E and Braf+/+ MEFs following AdCre treatment. Due to
the presence of polyadenylation sequences within the LSL cassette,
the BrafLSL-V600E allele is known to generate a hypomorphic Braf alleleFig. 2.Downregulation of BRAFprotein levels following V600EBRAF expression in the lung. (A)Histo
of age and Braf+/LSL-V600E; CreER™mice at 3, 6 and 10 weeks of age were generated and represen
reported in [36]. (B) Drop in BRAF protein levels following BRAFV600E expression. Soluble protein
(VE) mice at the ages shown using GLB lysis. Representative immunoblot analysis of protein lysathat expresses the BRAF protein at b10% the level of the wild-type
Braf allele (Fig. 1B). Thus, following removal of the LSL cassette,
BRAF protein levels within the Braf+/LSL-V600E cells are increased at
24 h following AdCre delivery (Fig. 1B and C). However, at subse-
quent time points (72–96 h), there was a signiﬁcant decrease in
BRAF protein levels (Fig. 1B and C). Such alterations in the levels of
BRAF protein were not observed in Braf+/+ cells following a time
course of AdCre treatment, suggesting they occur as a consequence
of V600EBRAF expression (Fig. 1B and C). This effect was not related
to cell density as indicated by the observation that BRAF levels do
not change in high or low-density cultures of Braf+/+ and Braf+/Lox-
V600E cells (Fig. 1D). The fact that BRAF levels drops by more than
50% in the Braf+/LSL-V600E cells would suggest that both WTBRAF and
V600EBRAF proteins are affected as a consequence of expression of
the oncogene.
The initial expression of V600EBRAFwas accompanied by induction of
phosphorylatedMEK/ERK at 24–48 h post-AdCre treatment (Fig. 1B andlogical staining of lung tissuewithH&E. Lung sections from Braf+/+;CreER™mice at 10weeks
tative H&E stained images are shown. Scale bars, 100 μm. These mice have been previously
lysates were generated from the lungs of Braf+/+; CreER™ (WT) and Braf+/LSL-V600E; CreER™
tes for BRAF, phosphoMEK and phosphoERK are shown. ERK2 was used as a loading control.
Fig. 3. Differences in BRAF protein levels are attributable to alterations in protein stability.
(A) Assessment of BrafmRNA levels. Quantitative RT-PCR (qRT-PCR) analysis was used to
investigate BrafmRNA levels in Braf+/LSL-V600E and Braf+/+ MEFs following a time course of
AdCre treatment. The graph shows the fold increase or decrease in Braf mRNA levels
relative to the levels in the Braf+/+ samples without AdCre (t = 0). Data represent
mean ± SD of three independent experiments of three independent MEFs of each
genotype. (B) Rescue of BRAF protein levels by proteasome inhibitors. Representative BRAF
immunoblot analysis of protein lysates derived from Braf+/Lox-V600E and Braf+/+ MEFs
following treatment with proteasomal inhibitors are shown. Braf+/+ and Braf+/LSL-V600E
MEFs were infected with AdCre for 96 h and treated either with DMSO, 30 μMMG132 in
DMSO or 0.5 μM Epoxomicin in DMSO for 5 h before harvesting soluble (SF) and insoluble
(IF) fractions. GAPDH and β-ACTIN were used as loading controls for the SF and IF
respectively. Data are representative of three experiments. (C) Half-life determination of
V600EBRAF and WTBRAF in HEK293T cells. Data were obtained in triplicate for three
independent experiments and the graph shows mean ± SD at each time point. The
average half-life of each sample is indicated.
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drop, there was a noticeable decrease in phosphorylated MEK/ERK
(Fig. 1B and E). This result suggests that the drop in BRAF expression
leads to downregulation in signalling through the MEK/ERK pathway.
To investigate whether similar responses occur in vivo, we assessed
BRAF protein levels in lung tissue derived from Braf+/LSL-V600E;CreER™
mice that develop lung adenomas at 3–10 weeks post-partum [36]
(Fig. 2A). As with the MEFs, BRAF protein levels were found to progres-
sively decrease in the V600EBRAF-expressing lung and thiswas accompa-
nied by a decrease in phosphorylated MEK and ERK levels at the 10-
week time points (Fig. 2B).
3.2. The decrease in BRAF protein level is associated with alterations in
protein stability
We quantitated BrafmRNA across the time course using qRT-PCR.
Braf mRNA levels were decreased in both Braf+/+ and Braf+/LSL-V600E
cells at 24–72 h post-AdCre treatment, suggesting this is a response to
the presence of Cre (Fig. 3A). However, at the 96 h time point, when
BRAF protein levels are most markedly decreased in the Braf+/LSL-V600E
cells (Fig. 1B, C and E), there was no signiﬁcant difference between
the expression of Braf mRNA in the Braf+/+ and Braf+/LSL-V600E MEFs
(Fig. 3A). This would suggest that the difference in protein expression
is not underpinned by transcriptional alterations in the Braf gene or
mRNA stability.
To investigate protein stability, the Braf+/+ and Braf+/LSL-V600E MEFs
at 96 h post-AdCre treatment were exposed to proteasomal inhibitors
MG132 and epoxomicin. For these experiments, soluble and insoluble
protein lysates were generated and analysed since proteasomal inhibi-
tion is known to lead to the accumulation of ubiquitylated proteins pre-
dominantly in detergent-insoluble fractions. Treatment with both
inhibitors led to an accumulation of BRAF protein levels in soluble and
insoluble fractions in both cell types (Fig. 3B). Indeed this treatment
raised BRAF protein levels in the AdCre-treated Braf+/LSL-V600E cells to
those similar to levels in AdCre-treated Braf+/+ cells without inhibitor
(Fig. 3B).
We also investigated the half-lives of WTBRAF and V600EBRAF by
transfecting vectors expressing MYC-tagged versions of either of the
proteins into HEK293T cells and using pulse–chase analysis. As shown
in Fig. 3C, ectopic V600EBRAF demonstrated a signiﬁcantly shorter half-
life than ectopic WTBRAF by ~3 h.
3.3. The decrease in BRAF protein level is associated with MEK activity
The fact that BRAF protein levels drop in the AdCre-treated
Braf+/LSL-V600E MEFs (Fig. 1C) suggests that both WTBRAF and
V600EBRAF proteins are affected by the presence of the oncogene
and therefore that a downstream event is involved in this regula-
tion. To examine a role of the MEK/ERK pathway, we treated
Braf+/LSL-V600E MEFs with the MEK inhibitor PD184352 and found
that this increased BRAF protein levels in both insoluble and soluble
protein fractions compared to controls (Fig. 4A). Furthermore, treat-
ment with PD184352 rescued the half-life of V600EBRAF to levels
similar to WTBRAF in HEK293T cells (Fig. 4B). Thus, the increased in-
stability of the BRAF protein following V600EBRAF expression can be
explained by ERK feedback regulation.
3.4. Association of feedback pathway with Oncogene-induced Senescence
(OIS)
V600EBRAF expression in primary mouse and human cells is known to
be associatedwithOIS [41–45]. To investigatewhether the feedbackpath-
way identiﬁed here is associated with OIS, we analysed the V600EBRAF-
expressingMEFs andHEK293T cells by immunoblotwith a range of senes-
cence markers (Fig. S1). Although the HEK293T cells only demonstrated
weak OIS marker expression, the MEFs demonstrated induction ofp21CIP1 and p19ARF expression at the late time points. Similarly, we have
previously demonstrated expression of senescence markers (p21CIP1
and γH2AX) in the lung tissue analysed in Fig. 2 at the 10 week time
point [36] when BRAF levels are observed to drop (Fig. 2B).
To further conﬁrm an association with OIS, we investigatedwhether
the feedback pathway is operational in advanced, highly proliferative
human cancer samples with long-term V600EBRAFmutation acquisition.
To this end, three human cancer cell lines Colo205, HT29 (both from co-
lorectal cancers) and A375 (from a melanoma) bearing the V600EBRAF
Fig. 4.BRAFprotein levels are increased byMEK inhibition. (A)MEK inhibition inMEFs. RepresentativeBRAF immunoblot analysis of protein lysates derived fromSF and IF ofBraf+/LSL-V600E
MEFs following treatment with MEK inhibitor 1 μM PD184352 or carrier control are shown. ERK2 and β-ACTIN were used as loading controls for the SF and IF respectively. Data are
representative of two experiments. (B) Half-life determination of V600EBRAF in HEK293T cells following treatment with 1 μM PD184352 (+PD) or carrier control (−PD). Data were
obtained in triplicate for two independent experiments and the graph shows mean ± SD at each time points. The average half-life of each treatment is indicated. (C) No alteration in
BRAF levels in human cancer cell lines following MEK inhibition. Colo205, A375 and HT29 were treated with 1 μM PD184352 (+PD) or carrier control (−PD) for 6–48 h. Protein
lysates were immunoblotted for BRAF and phosphoERK. GAPDH was used as a loading control. Of note, the human cancer cell lines used for this analysis do not carry mutations in
FBXW7 or known F-box containing genes (http://cancer.sanger.ac.uk/cosmic), as documented to date.
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levels were assessed. Although this treatment resulted in a noticeably
faster migrating form of BRAF, reﬂecting inhibition of ERK phosphoryla-
tion of BRAF [15], there were no alterations in BRAF expression levels in
any of the cell lines (Fig. 4C).3.5. BRAF stability is regulated by ERK phosphorylation sites within the CPD
Although a number of pathways controlling BRAF protein stability
have been identiﬁed and reported in the literature, given the role of
the ERK pathway (Fig. 4), we were particularly interested in the report-
ed control of LIN-45 stability by MPK1 and SEL-10 (FBXW7, FBW7 or
CDC4 in mammals) in C. elegans [33]. FBXW7 is a subunit of the SCF
complex [46,47]. Substrates for SCF have a high afﬁnity-binding site
for FBXW7 within a CPD [48–50] and LIN-45 contains an ERK docking
site D domain adjacent to the CPD with MPK1 capable of phosphorylat-
ing two residues (T432 and S436) within this CPD, allowing binding of
FBXW7. A conserved CPD is located at residues 400–405 in humanBRAF with ERK phosphorylation sites identiﬁed at residues T401 and
S405 (Fig. 5A).
To investigate the role of this putative CPD in mammalian BRAF
turnover, we mutated T401 and S405 to non-phosphorylatable alanine
residueswithinMyc-tagged human V600EBRAF as single and doublemu-
tations and tested their effect on protein stability (Fig. 5B). Both of the
single mutations (T401A or S405A) led to a substantial increase in the
half-life of V600EBRAF compared to the non-mutated versions and the
double mutation did not increase the half-life any further (Fig. 5B).
This suggests that phosphorylation of both T401 and S405 is important
in regulating the turnover of V600EBRAF. The half-lives of all CPD phos-
phorylation mutants in V600EBRAF were also increased by 4–5 h above
that for WTBRAF, suggesting that disruption of the CPD may interfere
with other pathways normally involved in the regulation of BRAF
turnover.
To conﬁrm thatmutation of these residueswithin the CPD itself does
not interfere with downstream signalling of V600EBRAF, we were able to
show that the mutants induced ERK phosphorylation to the same levels
as the non-mutated version of V600EBRAF (Fig. 5C) and they were also
Fig. 5. BRAF turnover is regulated by ERK phosphorylation in the CPD. (A) Schematic of human BRAF to indicate potential conserved CPD at residues 400–405 and putative ERK
phosphorylation sites at T401 and S405. T401 has previously been validated as a bona-ﬁde ERK phosphorylation site using experimentation [15]. (B) Half-life determination of
V600EBRAF, WTBRAF and V600EBRAF with CPD mutations in HEK293T cells. Data were obtained in triplicate for three independent experiments and the graph shows mean ± SD at each
time point. TS;V600EBRAF represents V600EBRAF with non-mutated CPD, AA;V600EBRAF represents V600EBRAF with the T401A;S405A double mutation in the CPD, AS;V600EBRAF represents
V600EBRAF with the T401A single mutation in the CPD and TA;V600EBRAF represents V600EBRAF with the S405A single mutation in the CPD. The average half-life of each mutant is
indicated. The data for non-CPD mutated WTBRAF and V600EBRAF are the same as that shown in Fig. 3C. (C) Immunoblot analysis of phosphoERK and MYC in protein lysates derived
from HEK293T cells transfected with empty vector (EV), the MYC-tagged WTBRAF expression vector and the MYC-tagged V600EBRAF expression vector with or without CPD mutations
for 48 h. GAPDH was used as a loading control. (D) Photographs of NIH3T3 cells that were transfected with empty vector (EV) or the MYC-tagged V600EBRAF vector with or without
CPD mutations for 48 h.
567M.A. Hernandez et al. / Cellular Signalling 28 (2016) 561–571able to induce morphological transformation of NIH3T3 cells (Fig. 5D).
This result is consistentwith previous data showing that the T401Amu-
tation does not have a strong effect on BRAF transforming activity [15].
3.6. The role of FBXW7 in BRAF turnover
To investigate a role of FBXW7 in mammalian BRAF protein turn-
over, we ﬁrst examined whether the two proteins are able to interact.
HEK293T cells were co-transfected with vectors expressing GFP alone,
GFP-tagged WTBRAF or GFP-tagged V600EBRAF with FLAG-tagged
FBXW7. Soluble protein lysates were generated, immunoprecipitated
using GFP trap beads and analysed by immunoblot for FLAG (Fig. 6A).
The data show co-immunoprecipitation of FBXW7 with WTBRAF and
V600EBRAF but not with GFP alone (Fig. 6A).
FBXW7 is involved in the binding of a number of substrates through
a C terminal interacting domainmade up ofWD40 repeats, and arginine
residues within these repeats are important for substrate recognition
[48,51]. Mutation of arginine residues at 465 and 479 within theWD40 repeats are hotspots for mutations in human cancers [50,52]
andmutation of the equivalent R479mutation inmice (R482) generates
increased expression of FBXW7 target substrates KLF5 and Tgiﬂ in the
mouse lung [37]. To investigate if R482 of mouse FBXW7 is involved
in the binding of BRAF we repeated the above coimmunoprecipitation
experiment with R482QFBXW7. This mutated form of FBXW7 was able
to interact with BRAF in a similar manner to WTFBXW7, suggesting the
interaction with BRAF is not mediated by the substrate recognition do-
main of FBXW7 (Fig. 6A).
We then performed over expression and loss of function studies to
address the role of FBXW7 in the turnover of both WTBRAF and
V600EBRAF. Using the HEK293T system the half-lives of WTBRAF and
V600EBRAF in the presence and absence of overexpressed FBXW7 were
compared. As shown in Fig. 6B, the half-lives of both WTBRAF and
V600EBRAF were not shortened by the co-overexpression of FBXW7,
counteracting the view that FBXW7 is involved in promotingBRAF turn-
over. In fact, the half-lives of both proteins was observed to increase in
the presence of over-expressed FBXW7 (although not to statistically
Fig. 6. FBXW7 interacts with BRAF in HEK293T but does not promote BRAF turnover. (A) Co-immunoprecipitation of BRAF with wild-type and mutant FBXW7. HEK293T cells were co-
transfected with vectors expressing GFP-tagged WTBRAF (WT), V600EBRAF (VE) or GFP alone (EV) together with either a vector expressing FLAG-tagged WTFBXW7 (top panels) or
R482QFBXW7 (bottom panels). After 48 h, soluble protein cell lysates (WCL) were generated and these were subjected to immunoblot for GFP or FLAG. GFP-expressing proteins were
immunoprecipitated using GFP-trap beads and these were subjected to immunoblot for FLAG (right panels) to examine co-immunoprecipitation of FBXW7 with BRAF. (B) Half-life de-
termination of V600EBRAF and WTBRAF in the absence or presence of over-expressed FBXW7 in HEK293T cells. HEK293T cells were transfected with vectors expressing MYC-tagged
WTBRAF or V600EBRAF in the presence or absence of a vector expressing FBXW7. Data were obtained in triplicate for three independent experiments and the graph shows mean ± SD
at each time point. The average half-life of each condition is indicated. The data for WTBRAF and V600EBRAF are the same as that shown in Fig. 3C.
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FBXW7 interferes with the binding of other proteins involved in regu-
lating BRAF turnover.
To further investigate a role of FBXW7 we ﬁrst attempted to under-
take Fbxw7 siRNA knockdown experiments in MEFs. However, these
proved not to be successful due to the lack of speciﬁc antibodies for en-
dogenous mouse FBXW7 (data not shown). As an alternative, we de-
rived MEFs from mice homozygous for a ﬂoxed allele for the
conditional knockin R482QFbxw7mutation [37] and examined BRAF pro-
tein expression following Cre-mediated recombination of the ﬂoxed al-
lele. As shown in Fig. 7A, the expression level of WTBRAFwas not altered
following R482QFBXW7 expression.
A similar experiment was performed with V600EBRAF in MEFs. MEFs
were derived from mouse embryos containing the Braf+/LSL-V600E allele
with orwithout the conditional homozygous knockin R482QFbxw7muta-
tion.MEFswere treatedwith AdCre for 96 h, and the expression of BRAF
was compared. On the R482QFbxw7mutant background, the expression
level of V600EBRAF was not signiﬁcantly altered compared to controls
(Fig. 7B). Additionally, there were no alterations in the morphological
transformation of the MEFs (Fig. 7C). These data are consistent with
the view that FBXW7 does not play a unique role in regulating the turn-
over of V600EBRAF.
4. Discussion
Exquisite control of the RAF–MEK–ERK signalling pathway is of crit-
ical importance in themaintenance of tissue and body homeostasis and
deregulation of the pathway is associated with several human patholo-
gies including cancer, RASopathies, some neurological disorders and di-
abetes [53]. An understanding of the mechanisms that regulate the
pathway in normal and diseased cells is imperative for the design ofoptimal treatments as well as for understanding drug resistance. Here
we have conﬁrmed the existence of an ERK-mediated feedback path-
way controlling BRAF protein turnover in mammalian cells that was
previously identiﬁed in C. elegans [33]. However, despite conservation
of the feedback loop via ERK, the subsequent BRAF degradation is differ-
ent in C. elegans and mammalian cells in that mammalian cells do not
uniquely rely on the FBXW7/SEL-10 component of the SCF E3 ubiquitin
ligase complex.
A variety of different methods for ﬁne-tuning the RAF–MEK–ERK
pathway have been identiﬁed in recent years, with a central point of
control existing at the level of RAF, which can be controlled by both
feedback and feed-forward mechanisms [9]. Regulation of RAF activity
involves cycles of phosphorylation and de-phosphorylation and has be-
come increasingly more complex with the discovery that RAF isoforms
can form RAF homo/hetero dimers with different levels of kinase activ-
ity [12]. RAF is also part of a multiprotein complex, components of
which can inﬂuence protein folding, stability and consequently activity
[28–30]. With regard to the control of RAF protein stability, a require-
ment for CRAF autophosphorylation of residue S621 has been reported
[40]. However, this mode of control was found not to be conserved for
BRAF [40] but, instead, we have conﬁrmed an involvement of MEK/
ERK activity in the regulation of BRAF protein stability.
This regulation of BRAF protein stability by ERK extends the reper-
toire of feedback mechanisms by which ERK controls output of the
RAF/MEK/ERK pathway. It has been previously documented that
ERK1/2 can down-regulate MEK1 activity by phosphorylation of T292
and T386 [54,55], although the control of cellular MEK1 levels by ERK-
dependent transcriptional methods has also been identiﬁed recently
[56]. ERK control of upstream regulators has also been documented in-
cluding the phosphorylation of SOS to regulate its interactionwith GRB2
[57] and disruption of the CRAF–RAS interaction by phosphorylation of
Fig. 7.Mutation of FBXW7 does not affect WTBRAF or V600EBRAF expression inMEFs. (A) Expression of WTBRAF inMEFswith the homozygous R482QFbxw7mutation. MEFs homozygous for
the Fbxw7ﬂ/ﬂ allele were treated with or without AdCre for 96 h. Protein lysates were generated and immunoblotted for BRAF. GAPDH was used as a loading control. DNA was also
generated and subjected to PCR for the Cre-deleted R482QFbxw7 ﬂoxed allele. Quantitation of BRAF protein levels is shown in the bar graph on the right. Data represent mean ± SD of
three independent experiments of three independent MEFs. (B) Expression of V600EBRAF in MEFs with or without the homozygous R482QFbxw7 mutation. MEFs were generated from
mice that contained the LSL-V600EBraf genetic modiﬁcation with (Mut) or without (WT) the Fbxw7ﬂ/ﬂ allele. MEFs were treated with AdCre for 96 h. Protein lysates were generated and
immunoblotted for BRAF. GAPDH was used as a loading control. DNA was also generated and subjected to PCR for the Cre-recombined LSL-V600EBraf allele and the Cre-deleted Fbxw7
ﬂoxed allele. Quantitation of BRAF protein levels is shown in the bar graph on the right. Data represent mean ± SD of three independent experiments of three independent MEFs.
(C) Morphology of Braf+/LSL-V600E MEFs with or without the homozygous Fbxw7R482Q mutation treated with AdCre for 96 h.
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phosphorylation sites are known to exist at S151, T401, S750 and
T753 and phosphorylation of all of the sites has been shown to contrib-
ute to disruption of BRAF/CRAF heterodimerisation [12,15]. We now
show that ERK phosphorylation of T401 and S405 has an additional
function in controlling BRAF protein stability.
We were ﬁrst drawn to investigating BRAF protein turnover by the
observation that BRAF protein levels are signiﬁcantly decreased in
mouse cells and tissue expressing autochthonous BRAF following
short term V600EBRAF expression (Figs. 1 and 2). This ﬁnding was sup-
ported by observations in the HEK293T over-expression systems, dem-
onstrating a shorter half-life of V600EBRAF than WTBRAF (Figs. 3–5).
The physiological role of this feedback mechanism is presently notclear, although our data (Fig. S1) suggest a potential link with the OIS
phenotype. Short-termexpression of V600EBRAF is known to be associat-
ed with the induction of senescence in themouse lungmodel [36,42] as
well as V600EBRAF intestinal [43] andmelanomamousemodels [44] and
the RAF/MEK/ERK pathway is known to mediate growth inhibitory sig-
nalling as well as cell proliferation [58]. Low levels of phospho-ERK are
associated with this phenotype in the mouse lung models (Fig. 2 and
[59]) and, furthermore, human melanocytic naevi bearing the
V600EBRAF oncogene demonstrate hallmarks of senescence [45] but
b25% show detectable phospho-ERK immunohistochemical staining
[60]. On this basis it has been suggested that feedback loopsmay be a re-
quirement for maintenance of V600EBRAF-induced senescence [60] as
has been documented for oncogenic RAS-induced senescence [61].
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feedback loops associated with the RAF/MEK/ERK pathway including
autochthonous mutation of ERK phosphorylation sites within the CPD
and correlation with physiological responses. The fact that the ERK-
mediated control of BRAF protein stability is not detected in human can-
cer cell lines (Fig. 4C), is consistent with a hypothesis that advanced
cancers have evolvedmechanisms to overcome this feedback regulation
in order to bypass OIS.
FBXW7 is a member of the F-box protein family, which contain
seven tandemWD40 repeats besides the F box, and is a substrate recep-
tor component of the SCF ubiquitin ligase complex. Substrate phosphor-
ylation within a CPD motif instigates FBXW7 binding leading to
degradation of the substrate by the SCF complex [50]. Indeed, FBXW7
mutations are associated with many human cancers and FBXW7 has
been implicated as a tumour suppressor by targeting the degradation
of oncoprotein substrates including Cyclin E, Notch 1 and C-Myc. Al-
though we found that FBXW7 is capable of binding BRAF, neither the
binding nor stability of BRAF was affected by the R482QFBXW7mutation
within its WD40 substrate recognition domain (Figs. 6 and 7), the
equivalentmutation of which (R479Q) is detected in many human can-
cers. Taken together, these results suggest that other E3 ubiquitin ligase
complexes are involved in regulating BRAF turnover, the identity of
which has yet to be revealed. Our data currently do not rule out a role
of other components of the SCF complex or F-box proteins.
In summary, our data show that BRAF protein stability is controlled
by a negative feedback loop involving ERK phosphorylation of T401
and S405 within a conserved CPD. Although this feedback pathway is
activated upon short-term expression of V600EBRAF, its functional role
in mediating proliferative/senescence responses are not clear and will
require further investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2016.02.009.
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